SM
NRXP icon

Sabby Management’s NRX Pharmaceuticals NRXP Stock Holding History

Sabby Management’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-768
Closed -$130K – 39
2024
Q3 		$130K Buy
768
+238
+45% +$479 0.07% 22
2024
Q2 		$129K Buy
+530
New +$1.89K 0.09% 25
2022
Q2 		– Sell
-181
Closed -$444K – 141
2022
Q1 		$444K Sell
181
-60
-25% -$1.95K 0.07% 65
2021
Q4 		$1.15M Buy
241
+148
+159% +$10.7K 0.17% 72
2021
Q3 		$858K Buy
+93
New +$12.1K 0.12% 93

Other funds holding NRXP

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OWMIAS
One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return

Sabby Management's NRXP Position: Q4 2024 in Review

Sabby Management sold out of NRX Pharmaceuticals (NRXP) in Q4 2024, closing a stake of 35,049 shares — an estimated $59.2K sold.

Sabby Management first reported a position in NRXP in Q1 2022 and held it in 5 quarters. The position peaked at $1.92M in Q1 2022. 25 funds tracked by Wall St. Rank hold NRXP as of Q4 2024.

  • Sabby Management reported no remaining NRX Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Sabby Management sold 35,049 NRX Pharmaceuticals shares in Q4 2024, an estimated $59.2K.
  • Sabby Management first reported a position in NRX Pharmaceuticals in Q1 2022 and held it in 5 quarters.
  • Sabby Management's NRX Pharmaceuticals position peaked at $1.92M in Q1 2022.
  • 25 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2024.

Based on Sabby Management's 13F filing for Q4 2024, filed 14 Feb 2025.